Standard

Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target. / Houdt, W.J.; Emmink, B.L.; Pham, T.; Piersma, S.; Verheem, A.; Vries, R.G.J.; Fratantoni, S.; Pronk, A.; Clevers, H.; Rinkes, I.H.; Jimenez, C.R.; Kranenburg, O.

In: Molecular and Cellular Proteomics, Vol. 10, No. 12, 2011, p. 111-11353.

Research output: Scientific - peer-reviewArticle

Harvard

Houdt, WJ, Emmink, BL, Pham, T, Piersma, S, Verheem, A, Vries, RGJ, Fratantoni, S, Pronk, A, Clevers, H, Rinkes, IH, Jimenez, CR & Kranenburg, O 2011, 'Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target' Molecular and Cellular Proteomics, vol 10, no. 12, pp. 111-11353. DOI: 10.1074/mcp.M111.011353

APA

Houdt, W. J., Emmink, B. L., Pham, T., Piersma, S., Verheem, A., Vries, R. G. J., ... Kranenburg, O. (2011). Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target. Molecular and Cellular Proteomics, 10(12), 111-11353. DOI: 10.1074/mcp.M111.011353

Vancouver

Houdt WJ, Emmink BL, Pham T, Piersma S, Verheem A, Vries RGJ et al. Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target. Molecular and Cellular Proteomics. 2011;10(12):111-11353. Available from, DOI: 10.1074/mcp.M111.011353

Author

Houdt, W.J.; Emmink, B.L.; Pham, T.; Piersma, S.; Verheem, A.; Vries, R.G.J.; Fratantoni, S.; Pronk, A.; Clevers, H.; Rinkes, I.H.; Jimenez, C.R.; Kranenburg, O. / Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target.

In: Molecular and Cellular Proteomics, Vol. 10, No. 12, 2011, p. 111-11353.

Research output: Scientific - peer-reviewArticle

BibTeX

@article{f26a467f468d475ba98f39fa7f23daa8,
title = "Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target",
abstract = "Patients with liver metastases from colon carcinoma show highly variable responses to chemotherapy and tumor recurrence is frequently observed. Therapy-resistant cancer stem cells have been implicated in drug resistance and tumor recurrence. However, the factors determining therapy resistance and tumor recurrence are poorly understood. The aim of this study was to gain insight into these mechanisms by comparing the proteomes of patient-derived cancer stem cell cultures and their differentiated isogenic offspring. We established colonosphere cultures derived from resection specimens of liver metastases in patients with colon cancer. These colonospheres, enriched for colon cancer stem cells, were used to establish isogenic cultures of stably differentiated nontumorigenic progeny. Proteomics based on one-dimensional gel electrophoresis coupled to nano liquid chromatography tandem MS was used to identify proteome differences between three of these paired cultures. The resulting data were analyzed using Ingenuity Pathway Software. Out of a total data set of 3048 identified proteins, 32 proteins were at least twofold up-regulated in the colon cancer stem cells when compared with the differentiated cells. Pathway analysis showed that {"}cell death {"} regulation is strikingly different between the two cell types. Interestingly, one of the top-up-regulated proteins was BIRC6, which belongs to the class of Inhibitor of Apoptosis Proteins. Knockdown of BIRC6 sensitized colon cancer stem cells against the chemotherapeutic drugs oxaliplatin and cisplatin. This study reveals that differentiation of colon cancer stem cells is accompanied by altered regulation of cell death pathways. We identified BIRC6 as an important mediator of cancer stem cell resistance against cisplatin and oxaliplatin. Targeting BIRC6, or other Inhibitors of Apoptosis Proteins, may help eradicating colon cancer stem cells.",
author = "W.J. Houdt and B.L. Emmink and T. Pham and S. Piersma and A. Verheem and R.G.J. Vries and S. Fratantoni and A. Pronk and H. Clevers and I.H. Rinkes and C.R. Jimenez and O. Kranenburg",
note = "Reporting year: 2011",
year = "2011",
doi = "10.1074/mcp.M111.011353",
volume = "10",
pages = "111--11353",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "12",

}

RIS

TY - JOUR

T1 - Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target

AU - Houdt,W.J.

AU - Emmink,B.L.

AU - Pham,T.

AU - Piersma,S.

AU - Verheem,A.

AU - Vries,R.G.J.

AU - Fratantoni,S.

AU - Pronk,A.

AU - Clevers,H.

AU - Rinkes,I.H.

AU - Jimenez,C.R.

AU - Kranenburg,O.

N1 - Reporting year: 2011

PY - 2011

Y1 - 2011

N2 - Patients with liver metastases from colon carcinoma show highly variable responses to chemotherapy and tumor recurrence is frequently observed. Therapy-resistant cancer stem cells have been implicated in drug resistance and tumor recurrence. However, the factors determining therapy resistance and tumor recurrence are poorly understood. The aim of this study was to gain insight into these mechanisms by comparing the proteomes of patient-derived cancer stem cell cultures and their differentiated isogenic offspring. We established colonosphere cultures derived from resection specimens of liver metastases in patients with colon cancer. These colonospheres, enriched for colon cancer stem cells, were used to establish isogenic cultures of stably differentiated nontumorigenic progeny. Proteomics based on one-dimensional gel electrophoresis coupled to nano liquid chromatography tandem MS was used to identify proteome differences between three of these paired cultures. The resulting data were analyzed using Ingenuity Pathway Software. Out of a total data set of 3048 identified proteins, 32 proteins were at least twofold up-regulated in the colon cancer stem cells when compared with the differentiated cells. Pathway analysis showed that "cell death " regulation is strikingly different between the two cell types. Interestingly, one of the top-up-regulated proteins was BIRC6, which belongs to the class of Inhibitor of Apoptosis Proteins. Knockdown of BIRC6 sensitized colon cancer stem cells against the chemotherapeutic drugs oxaliplatin and cisplatin. This study reveals that differentiation of colon cancer stem cells is accompanied by altered regulation of cell death pathways. We identified BIRC6 as an important mediator of cancer stem cell resistance against cisplatin and oxaliplatin. Targeting BIRC6, or other Inhibitors of Apoptosis Proteins, may help eradicating colon cancer stem cells.

AB - Patients with liver metastases from colon carcinoma show highly variable responses to chemotherapy and tumor recurrence is frequently observed. Therapy-resistant cancer stem cells have been implicated in drug resistance and tumor recurrence. However, the factors determining therapy resistance and tumor recurrence are poorly understood. The aim of this study was to gain insight into these mechanisms by comparing the proteomes of patient-derived cancer stem cell cultures and their differentiated isogenic offspring. We established colonosphere cultures derived from resection specimens of liver metastases in patients with colon cancer. These colonospheres, enriched for colon cancer stem cells, were used to establish isogenic cultures of stably differentiated nontumorigenic progeny. Proteomics based on one-dimensional gel electrophoresis coupled to nano liquid chromatography tandem MS was used to identify proteome differences between three of these paired cultures. The resulting data were analyzed using Ingenuity Pathway Software. Out of a total data set of 3048 identified proteins, 32 proteins were at least twofold up-regulated in the colon cancer stem cells when compared with the differentiated cells. Pathway analysis showed that "cell death " regulation is strikingly different between the two cell types. Interestingly, one of the top-up-regulated proteins was BIRC6, which belongs to the class of Inhibitor of Apoptosis Proteins. Knockdown of BIRC6 sensitized colon cancer stem cells against the chemotherapeutic drugs oxaliplatin and cisplatin. This study reveals that differentiation of colon cancer stem cells is accompanied by altered regulation of cell death pathways. We identified BIRC6 as an important mediator of cancer stem cell resistance against cisplatin and oxaliplatin. Targeting BIRC6, or other Inhibitors of Apoptosis Proteins, may help eradicating colon cancer stem cells.

U2 - 10.1074/mcp.M111.011353

DO - 10.1074/mcp.M111.011353

M3 - Article

VL - 10

SP - 111

EP - 11353

JO - Molecular and Cellular Proteomics

T2 - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 12

ER -

ID: 245687